Doma Pharmaceutical Technology

Doma Pharmaceutical Technology is a China-based biotechnology company and incubator founded in 2021 and headquartered in Suzhou BioBAY. Established by Biocytogen and a consortium of leading institutional investors, the company operates as a fully integrated life science innovation platform that combines drug discovery with industrial incubation. Doma focuses on developing next-generation therapeutic modalities, particularly bispecific antibody-drug conjugates (BsADCs) and cell therapies, leveraging Biocytogen's proprietary RenLite and RenBiologics platforms. The company's lead programs, including DM001 (EGFR/TROP2 BsADC) and DM005 (EGFR/c-MET BsADC), have advanced into global Phase 1 clinical trials for the treatment of various advanced solid tumors. Doma also provides comprehensive support to its incubated subsidiaries, such as Xadcera Biopharmaceutical and Stow Pharmaceutical, to accelerate the translation of innovative biotechnologies into clinical products.